RECRUITING

Cognitive Assessment Tools for Huntington's Disease.

Talk to us

Conditions

Huntington DiseaseSelf-Administered Gerocognitive Examination (SAGE)Coding

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is the Self-Administered Gerocognitive Examination (SAGE). Both the Coding Test and the SAGE have been used for assessments of individuals with other neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease and Lewy Body Disease, but data is lacking on their use in individuals with HD.

Official Title

Cognitive Assessment Tools for Individuals With Huntington's Disease.

Quick Facts

Study Start:2025-06-20
Study Completion:2025-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06546488

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:30 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Not specified
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Males and females aged 30-65 (inclusive) at the time of signing the informed consent form.
  2. 2. Genetic diagnosis of HD as defined by a CAG repeat size ≥ 40.
  3. 3. A clinical diagnosis of HD as defined by a Diagnostic Confidence Level (DCL) of 4.
  4. 4. Vision and hearing sufficient for compliance with tests.
  5. 5. On a stable dose of medications for 30 days prior to the time of signing the informed consent form.
  1. 1. Age of symptom onset less than 19 years old or greater than 60 years old.
  2. 2. Any serious neurological disorder aside from HD, including but not limited to Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, Lewy body dementia, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury… etc. that in the opinion of the investigator is clinically significant.
  3. 3. Any ongoing serious medical condition that in the opinion of the investigator is clinically significant. This includes autoimmune diseases, ongoing treatment for cancer, congestive heart failure, severe pulmonary disease, or any history of a seizure disorder (including the need to take anti-epileptics to prevent seizure).
  4. 4. Subjects who are pregnant or breast feeding
  5. 5. Subjects with a history of a learning disability.
  6. 6. Subjects who are unable to provide consent.

Contacts and Locations

Study Contact

Nicole E Vrettos
CONTACT
6143668642
nicole.vrettos@osumc.edu

Study Locations (Sites)

The Ohio State University Wexner Medical Center
Columbus, Ohio, 43221
United States

Collaborators and Investigators

Sponsor: Ohio State University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06-20
Study Completion Date2025-12-01

Study Record Updates

Study Start Date2025-06-20
Study Completion Date2025-12-01

Terms related to this study

Keywords Provided by Researchers

  • Self-Administered Gerocognitive Examination (SAGE)
  • Coding
  • Huntington Disease

Additional Relevant MeSH Terms

  • Huntington Disease